![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/21/2885689/0/en/Lyra-Therapeutics-Announces-Cost-Cutting-Measures-to-Preserve-Capital.html
https://www.globenewswire.com/news-release/2024/05/06/2875729/0/en/Lyra-Therapeutics-Reports-Topline-Results-from-Phase-3-ENLIGHTEN-1-Trial-for-LYR-210-in-Chronic-Rhinosinusitis.html
https://www.globenewswire.com/news-release/2024/04/30/2872758/0/en/Lyra-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/04/26/2870754/0/en/Lyra-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/03/21/2850605/0/en/Lyra-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/03/01/2839056/0/en/Lyra-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2023/11/07/2774905/0/en/Lyra-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2023/11/07/2775550/0/en/Lyra-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2023/10/16/2760477/0/en/Lyra-Therapeutics-Announces-Appointment-of-Ronan-O-Brien-as-Chief-Legal-Officer.html
https://www.globenewswire.com//news-release/2023/09/12/2741489/0/en/Lyra-Therapeutics-Announces-Positive-Topline-Results-from-BEACON-Phase-2-Study-of-LYR-220-for-the-Treatment-of-Chronic-Rhinosinusitis-CRS-in-Patients-with-Prior-Ethmoid-Sinus-Surge.html